MX377802B - Metodos y composiciones para trastornos del sueño y otros trastornos. - Google Patents
Metodos y composiciones para trastornos del sueño y otros trastornos.Info
- Publication number
- MX377802B MX377802B MX2015004044A MX2015004044A MX377802B MX 377802 B MX377802 B MX 377802B MX 2015004044 A MX2015004044 A MX 2015004044A MX 2015004044 A MX2015004044 A MX 2015004044A MX 377802 B MX377802 B MX 377802B
- Authority
- MX
- Mexico
- Prior art keywords
- disorders
- compositions
- methods
- sleep
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
- A01N43/42—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Plant Pathology (AREA)
- Agronomy & Crop Science (AREA)
- Environmental Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Dentistry (AREA)
- Pest Control & Pesticides (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5643308P | 2008-05-27 | 2008-05-27 | |
| US15503209P | 2009-02-24 | 2009-02-24 | |
| PCT/US2009/003261 WO2009145900A1 (en) | 2008-05-27 | 2009-05-27 | Methods and compositions for sleep disorders and other disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX377802B true MX377802B (es) | 2025-03-11 |
Family
ID=41377435
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015004044A MX377802B (es) | 2008-05-27 | 2009-05-27 | Metodos y composiciones para trastornos del sueño y otros trastornos. |
| MX2010013020A MX2010013020A (es) | 2008-05-27 | 2009-05-27 | Metodos y composiciones para trastornos del sueño y otros trastornos. |
| MX2020012868A MX2020012868A (es) | 2008-05-27 | 2010-11-26 | Metodos y composiciones para trastornos del sue?o y otros trastornos. |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010013020A MX2010013020A (es) | 2008-05-27 | 2009-05-27 | Metodos y composiciones para trastornos del sueño y otros trastornos. |
| MX2020012868A MX2020012868A (es) | 2008-05-27 | 2010-11-26 | Metodos y composiciones para trastornos del sue?o y otros trastornos. |
Country Status (9)
| Country | Link |
|---|---|
| US (10) | US8598119B2 (OSRAM) |
| EP (2) | EP2320731A4 (OSRAM) |
| JP (2) | JP6106361B2 (OSRAM) |
| KR (4) | KR102317698B1 (OSRAM) |
| CN (2) | CN102105059B (OSRAM) |
| AU (1) | AU2009251816B2 (OSRAM) |
| CA (1) | CA2725342C (OSRAM) |
| MX (3) | MX377802B (OSRAM) |
| WO (1) | WO2009145900A1 (OSRAM) |
Families Citing this family (72)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008052139A2 (en) | 2006-10-25 | 2008-05-02 | Somaxon Pharmaceuticals, Inc. | Ultra low dose doxepin and methods of using the same to treat sleep disorders |
| US20110077200A1 (en) * | 2006-12-06 | 2011-03-31 | Somaxon Pharmaceuticals, Inc. | Combination therapy using low-dose doxepin for the improvement of sleep |
| KR102372149B1 (ko) | 2007-03-12 | 2022-03-07 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로환 융합 감마-카르볼린 합성 |
| PL2262505T3 (pl) | 2008-03-12 | 2015-04-30 | Intra Cellular Therapies Inc | Podstawione heterocykliczne skondensowane gamma-karboliny w postaci stałej |
| US8598119B2 (en) | 2008-05-27 | 2013-12-03 | Intra-Cellular Therapies, Inc. | Methods and compositions for sleep disorders and other disorders |
| ES2735411T3 (es) | 2009-10-23 | 2019-12-18 | Janssen Pharmaceutica Nv | Octahidropirrolo[3,4-c]pirroles disustituidos como moduladores del receptor de orexina |
| US8993572B2 (en) * | 2010-04-22 | 2015-03-31 | Intra-Cellular Therapies, Inc. | Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives |
| US8741888B2 (en) * | 2010-11-09 | 2014-06-03 | Carl A. Forest | Sleep aid composition and method |
| WO2013009517A1 (en) * | 2011-07-08 | 2013-01-17 | Eli Lilly And Company | (THIENO[2,3-b][1,5]BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS |
| WO2013155504A1 (en) * | 2012-04-14 | 2013-10-17 | Intra-Cellular Therapies, Inc. | Novel methods |
| CN103175973B (zh) * | 2013-02-26 | 2015-05-13 | 首都医科大学 | 甘丙肽在制备女性抑郁症检测工具中的应用 |
| US11235020B2 (en) * | 2013-03-13 | 2022-02-01 | Abraham Palmer | Methods and compositions for inhibiting glyoxalase 1 (GLO1) |
| WO2014152804A1 (en) * | 2013-03-14 | 2014-09-25 | Hyperion Biotechnology | Methods and compositions for biomarkers of fatigue, fitness and physical performance capacity |
| WO2014145192A1 (en) | 2013-03-15 | 2014-09-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| IL321987A (en) | 2013-12-03 | 2025-09-01 | Intra Cellular Therapies Inc | A long-acting injectable preparation containing polymeric microspheres of modified compressed gamma-carboline heterocyclic compounds or a sustained-release pharmaceutical preparation containing these compounds for use in the treatment of bipolar I and/or bipolar II disorders |
| MX388258B (es) | 2014-04-04 | 2025-03-19 | Intra Cellular Therapies Inc | Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio. |
| AU2015240526A1 (en) | 2014-04-04 | 2016-11-24 | Intra-Cellular Therapies, Inc. | Organic compounds |
| KR20160103548A (ko) * | 2015-01-28 | 2016-09-01 | 주식회사 제네리스코리아 | 신경정신계 장애의 치료를 위한 조성물 및 방법 |
| WO2017117514A1 (en) * | 2015-12-31 | 2017-07-06 | Tung Roger D | Deuterated iti-007 |
| PT3407888T (pt) | 2016-01-26 | 2021-03-19 | Intra Cellular Therapies Inc | Compostos de piridopirroloquinoxalina, suas composições e utilizações |
| CA2960253A1 (en) | 2016-03-10 | 2017-09-10 | Janssen Pharmaceutica Nv | Methods of treating depression using orexin-2 receptor antagonists |
| JP6686168B2 (ja) | 2016-03-25 | 2020-04-22 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 有機化合物 |
| JP2019513143A (ja) * | 2016-03-28 | 2019-05-23 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規塩類および結晶 |
| JP2019510039A (ja) | 2016-03-28 | 2019-04-11 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規組成物および方法 |
| JP6997718B2 (ja) * | 2016-03-28 | 2022-01-18 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規共結晶 |
| EP3525763B1 (en) | 2016-10-12 | 2025-03-05 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
| WO2018126140A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US10906906B2 (en) | 2016-12-29 | 2021-02-02 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CN116327770B (zh) | 2017-03-24 | 2025-10-31 | 细胞内治疗公司 | 新组合物和方法 |
| CN110636845A (zh) * | 2017-04-10 | 2019-12-31 | 雷迪博士实验室有限公司 | 卢美哌隆对甲苯磺酸盐的无定形形式和固体分散体 |
| US9993486B1 (en) | 2017-06-19 | 2018-06-12 | Tlc Therapeutics, Llc | Oral quetiapine suspension formulations with extended shelf life and enhanced bioavailability |
| BR112020001666A2 (pt) | 2017-07-26 | 2020-07-21 | Intra-Cellular Therapies, Inc. | compostos orgânicos |
| IL272252B2 (en) * | 2017-07-26 | 2024-03-01 | Intra Cellular Therapies Inc | Derivatives of substituted heterocycle fused gamma-carbolines, pharmaceutical compositions comnprising them and their use in treatment |
| JP2020535231A (ja) | 2017-09-26 | 2020-12-03 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規な塩および結晶 |
| KR102036909B1 (ko) * | 2017-11-28 | 2019-10-25 | 한국과학기술원 | 신규 디스토니아 치료용 약학적 조성물 |
| CA3094204A1 (en) * | 2018-03-16 | 2019-09-19 | Intra-Cellular Therapies, Inc. | Novel methods |
| CA3095101A1 (en) | 2018-03-23 | 2019-09-26 | Intra-Cellular Therapies, Inc. | Deuterated octahydro-quinoxaline derivatives and pharmaceutical compositions thereof use in the treatment of diseases involving serotonin 5-ht2a, dopamine d1/d2 and/or serotonin reuptake transporter (sert) pathways |
| MX2020009928A (es) | 2018-03-23 | 2021-01-08 | Intra Cellular Therapies Inc | Compuestos organicos. |
| KR102888393B1 (ko) | 2018-06-06 | 2025-11-18 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 염 및 결정 |
| MX2020013335A (es) | 2018-06-08 | 2021-05-27 | Intra Cellular Therapies Inc | Metodos novedosos. |
| KR102778034B1 (ko) | 2018-06-11 | 2025-03-12 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로환 융합 감마-카르볼린 합성 |
| AU2019288476A1 (en) | 2018-06-21 | 2021-03-18 | Aquestive Therapeutics, Inc. | System and method for making personalized individual unit doses containing pharmaceutical actives |
| EP3843729A4 (en) * | 2018-08-29 | 2022-06-01 | Intra-Cellular Therapies, Inc. | NEW COMPOSITIONS AND METHODS |
| US10695345B2 (en) | 2018-08-31 | 2020-06-30 | Intra-Cellular Therapies, Inc. | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
| EP3843738A4 (en) | 2018-08-31 | 2022-06-01 | Intra-Cellular Therapies, Inc. | NEW METHODS |
| BR112021004053A2 (pt) | 2018-09-07 | 2021-05-25 | Aquestive Therapeutics, Inc. | composições de filme oral e formas de dosagem tendo perfis de dissolução de ativo precisos |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| MX2021007143A (es) | 2018-12-17 | 2021-08-18 | Intra Cellular Therapies Inc | Sintesis de gamma-carbolinas fusionadas con heterociclo sustituido. |
| WO2020131895A1 (en) | 2018-12-17 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
| CA3121635A1 (en) | 2018-12-17 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Serotonin 5-ht2a receptor antagonist |
| WO2020132474A1 (en) | 2018-12-21 | 2020-06-25 | Intra-Cellular Therapies, Inc. | Organic compound |
| US12331052B2 (en) | 2018-12-21 | 2025-06-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP7673040B2 (ja) | 2019-07-07 | 2025-05-08 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規方法 |
| WO2021062307A1 (en) | 2019-09-25 | 2021-04-01 | Intra-Cellular Therapies, Inc. | Novel methods |
| KR102227268B1 (ko) * | 2019-10-07 | 2021-03-12 | 한국과학기술원 | 디스토니아 치료 후보 약물의 신규 스크리닝 방법 |
| AU2020373100A1 (en) | 2019-11-01 | 2022-05-19 | Aquestive Therapeutics, Inc. | Prodrug compositions and methods of treatment |
| CA3159389A1 (en) | 2019-11-14 | 2021-05-20 | Aquestive Therapeutics, Inc. | Multimodal compositions comprising diazepam and methods of treatment |
| WO2021119334A1 (en) * | 2019-12-11 | 2021-06-17 | Intra-Cellular Therapies, Inc. | Organic compound |
| JP7727634B2 (ja) | 2019-12-19 | 2025-08-21 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 統合失調症処置方法 |
| BR112023005443A2 (pt) * | 2020-10-09 | 2023-05-09 | Shujing Biopharma Co Ltd | Derivado de y-carbolina fundido substituído heterocíclico, método de preparação do mesmo, intermediário do mesmo e uso do mesmo |
| CA3208345A1 (en) | 2021-01-15 | 2022-07-21 | Aquestive Therapeutics, Inc. | Prodrug compositions and methods of treatment |
| WO2022192476A1 (en) | 2021-03-09 | 2022-09-15 | Aquestive Therapeutics, Inc. | Dosage forms having equivalent biocomparable profiles |
| WO2023097316A1 (en) * | 2021-11-29 | 2023-06-01 | Editas Medicine, Inc. | Engineered crispr/cas12a effector proteins, and uses thereof |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
| CA3252857A1 (en) | 2022-05-18 | 2023-11-23 | Intra-Cellular Therapies, Inc. | NEW PROCESSES |
| CN115067220B (zh) * | 2022-06-16 | 2023-04-25 | 中国人民解放军军事科学院军事医学研究院 | 一种双通道小动物恐惧共情行为检测系统 |
| CN120282964A (zh) * | 2022-10-26 | 2025-07-08 | 上海枢境生物科技有限公司 | 一种杂环取代的稠合γ-咔啉类衍生物的甲磺酸盐、晶型及其制备方法和应用 |
| CA3274836A1 (en) | 2022-12-30 | 2024-07-04 | Intra-Cellular Therapies, Inc. | Fused heterocyclic gamma-carbolines acting on the 5-HT2A serotonin receptor |
| WO2024173901A1 (en) * | 2023-02-17 | 2024-08-22 | Intra-Cellular Therapies, Inc. | Lumateperone and derivatives thereof for modulating the nervous system |
| WO2025111568A1 (en) | 2023-11-22 | 2025-05-30 | Intra-Cellular Therapies, Inc. | Lumateperone and analogues, as 5-ht2a or 5-ht2a/d2 receptor modulators, for use in the treatment of psychiatric disorders caused by viral, bacterial, or autoimmune encephalitis, and of psychiatric symptoms thereof |
| KR20250129554A (ko) | 2024-02-22 | 2025-08-29 | 단국대학교 천안캠퍼스 산학협력단 | 드로페리돌을 유효성분으로 포함하는 신경 질환 예방 또는 치료용 약학 조성물 |
| WO2025240804A1 (en) | 2024-05-16 | 2025-11-20 | Intra-Cellular Therapies, Inc. | Novel compositions, devices and methods |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4162318A (en) * | 1976-05-05 | 1979-07-24 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Use of trazodone and etoperidone in Parkinsonism and in other extrapyramidal syndromes characterized by tremors |
| HU208484B (en) | 1988-08-17 | 1993-11-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia |
| US5114976A (en) | 1989-01-06 | 1992-05-19 | Norden Michael J | Method for treating certain psychiatric disorders and certain psychiatric symptoms |
| US7071186B2 (en) | 1999-06-15 | 2006-07-04 | Bristol-Myers Squibb Pharma Co. | Substituted heterocycle fused gamma-carbolines |
| US6713471B1 (en) | 1999-06-15 | 2004-03-30 | Bristol-Myers Squibb Pharma Company | Substituted heterocycle fused gamma-carbolines |
| AR024378A1 (es) | 1999-06-15 | 2002-10-02 | Du Pont Pharm Co | Gamma-carbolinas fusionadas heterociclicas sustituidas |
| US20050222209A1 (en) * | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
| MX2007008903A (es) | 2005-01-25 | 2007-09-07 | Celgene Corp | Metodos y composiciones que usan 4-amino-2-(3-metil-2,6- dioxopiperidin-3-il)-isoindol-1,3-diona. |
| WO2007025103A2 (en) | 2005-08-23 | 2007-03-01 | Intra-Cellular Therapies, Inc. | Organic compounds for treating reduced dopamine receptor signalling activity |
| KR20080114688A (ko) | 2006-01-13 | 2008-12-31 | 와이어쓰 | 5-히드록시트립타민 수용체에 대한 리간드로서의 술포닐 치환된 1ｈ-인돌 |
| CA2662491A1 (en) | 2006-09-08 | 2008-03-13 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| KR102372149B1 (ko) | 2007-03-12 | 2022-03-07 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로환 융합 감마-카르볼린 합성 |
| JP2010535220A (ja) | 2007-08-01 | 2010-11-18 | メディベイション ニューロロジー， インコーポレイテッド | 抗精神病用の併用療法剤を使用する統合失調症の治療のための方法および組成物 |
| MX2010008688A (es) | 2008-02-07 | 2010-08-30 | Schering Corp | Anticuerpos anti-receptor de linfopoyetina estromal timica procesados por ingenieria. |
| PL2262505T3 (pl) | 2008-03-12 | 2015-04-30 | Intra Cellular Therapies Inc | Podstawione heterocykliczne skondensowane gamma-karboliny w postaci stałej |
| US8598119B2 (en) * | 2008-05-27 | 2013-12-03 | Intra-Cellular Therapies, Inc. | Methods and compositions for sleep disorders and other disorders |
| US8993572B2 (en) | 2010-04-22 | 2015-03-31 | Intra-Cellular Therapies, Inc. | Pyrido[3′,4′:4,5]pyrrolo[1,2,3-de]quinoxalines derivatives and [1,4]oxazino[2,3,4-hi]pyrido[4,3-b]indole derivatives |
| WO2013155504A1 (en) | 2012-04-14 | 2013-10-17 | Intra-Cellular Therapies, Inc. | Novel methods |
| WO2014145192A1 (en) | 2013-03-15 | 2014-09-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| IL321987A (en) * | 2013-12-03 | 2025-09-01 | Intra Cellular Therapies Inc | A long-acting injectable preparation containing polymeric microspheres of modified compressed gamma-carboline heterocyclic compounds or a sustained-release pharmaceutical preparation containing these compounds for use in the treatment of bipolar I and/or bipolar II disorders |
| MX388258B (es) * | 2014-04-04 | 2025-03-19 | Intra Cellular Therapies Inc | Gamma-carbolinas fusionadas con heterociclos sustituidas con deuterio. |
| AU2015240526A1 (en) * | 2014-04-04 | 2016-11-24 | Intra-Cellular Therapies, Inc. | Organic compounds |
| PT3407888T (pt) * | 2016-01-26 | 2021-03-19 | Intra Cellular Therapies Inc | Compostos de piridopirroloquinoxalina, suas composições e utilizações |
| JP6997718B2 (ja) * | 2016-03-28 | 2022-01-18 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規共結晶 |
| JP2019513143A (ja) * | 2016-03-28 | 2019-05-23 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規塩類および結晶 |
| EP3525763B1 (en) * | 2016-10-12 | 2025-03-05 | Intra-Cellular Therapies, Inc. | Amorphous solid dispersions |
| IL272252B2 (en) * | 2017-07-26 | 2024-03-01 | Intra Cellular Therapies Inc | Derivatives of substituted heterocycle fused gamma-carbolines, pharmaceutical compositions comnprising them and their use in treatment |
| US10695345B2 (en) * | 2018-08-31 | 2020-06-30 | Intra-Cellular Therapies, Inc. | Pharmaceutical capsule compositions comprising lumateperone mono-tosylate |
-
2009
- 2009-05-27 US US12/994,560 patent/US8598119B2/en not_active Ceased
- 2009-05-27 CA CA2725342A patent/CA2725342C/en active Active
- 2009-05-27 EP EP09755263A patent/EP2320731A4/en not_active Ceased
- 2009-05-27 CN CN200980128888.4A patent/CN102105059B/zh active Active
- 2009-05-27 KR KR1020207033595A patent/KR102317698B1/ko active Active
- 2009-05-27 WO PCT/US2009/003261 patent/WO2009145900A1/en not_active Ceased
- 2009-05-27 KR KR1020167032085A patent/KR102133073B1/ko active Active
- 2009-05-27 KR KR1020197000911A patent/KR102184038B1/ko active Active
- 2009-05-27 AU AU2009251816A patent/AU2009251816B2/en active Active
- 2009-05-27 MX MX2015004044A patent/MX377802B/es unknown
- 2009-05-27 US US16/784,112 patent/USRE48839E1/en active Active
- 2009-05-27 KR KR1020107029327A patent/KR20110022631A/ko not_active Ceased
- 2009-05-27 JP JP2011511638A patent/JP6106361B2/ja active Active
- 2009-05-27 CN CN201510553160.3A patent/CN105168219B/zh active Active
- 2009-05-27 MX MX2010013020A patent/MX2010013020A/es active IP Right Grant
- 2009-05-27 EP EP16151760.2A patent/EP3085231A1/en not_active Withdrawn
-
2010
- 2010-11-26 MX MX2020012868A patent/MX2020012868A/es unknown
-
2013
- 2013-10-30 US US14/066,987 patent/US9168258B2/en active Active
-
2015
- 2015-04-02 JP JP2015076230A patent/JP2015157828A/ja active Pending
- 2015-10-16 US US14/885,813 patent/US9616061B2/en active Active
-
2017
- 2017-03-23 US US15/467,867 patent/US10117867B2/en active Active
-
2018
- 2018-10-19 US US16/165,832 patent/US10702522B2/en active Active
-
2020
- 2020-07-06 US US16/921,586 patent/US20200405713A1/en not_active Abandoned
-
2023
- 2023-02-15 US US18/169,466 patent/US20230355616A1/en not_active Abandoned
- 2023-10-04 US US18/481,170 patent/US20240041871A1/en not_active Abandoned
-
2024
- 2024-12-10 US US18/975,550 patent/US20250332164A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX377802B (es) | Metodos y composiciones para trastornos del sueño y otros trastornos. | |
| CL2012003604A1 (es) | Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros. | |
| MX2011008450A (es) | Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos. | |
| CL2012001605A1 (es) | Compuestos derivados de quinolina-2-carboxamida, moduladores alostericos positivos del receptor muscarino m1; composicion farmaceutica que comprende al compuesto; y su uso en la preparacion de medicamentos para el tratamiento de enfermedades tales como alzheimer, trastornos del dolor o del sueño. | |
| BR112012018386A8 (pt) | "inibidores isoindolinona de fosfatidilinositol 3-quinase" | |
| UA107814C2 (uk) | Спірооксіндольні антагоністи мdм2 | |
| MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
| MX2009006704A (es) | Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa. | |
| CO6440531A2 (es) | 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso | |
| PH12015501067A1 (en) | Pyrrolopyrimidine compounds as kinase inhibitors | |
| PE20121617A1 (es) | Derivados de oxazina como inhibidores de bace | |
| EP2582676A4 (en) | POSITIVE ALLOSTERIC TETRAHYDROCHINOLINE AMID M1 RECEPTOR MODULATORS | |
| HK1203489A1 (en) | Purinone compounds as kinase inhibitors | |
| CL2009000349A1 (es) | Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer. | |
| CL2008001932A1 (es) | Compuestos derivados de 6-cicloamino-3-(piridin-4-il)imidazo[1,2-b]piridazina, inhibidores de cq1epsilon y/o ck1delta; procedimiento de preparacion; composicion farmaceutica que los comprende; y uso en el tratamiento de desordenes del sueno, trastorno del ritmo circadiano, cancer y enfermedad de alzheimer. | |
| EA201201658A1 (ru) | Производные пиперидина и их применение для лечения метаболических нарушений | |
| CL2008001025A1 (es) | Compuestos derivados de pirimido[5,4-d]pirimidina-2,4,6,8-tetraona; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastorno metabolico, dislipidemia y cancer. | |
| CL2009000035A1 (es) | Compuestos derivados 3-espiro-heterociclo-1il-5h-ciclopentan[d]pirimidin-indol, util para inhibir la actividad de akt quinasa; composicion farmaceutica que comprende dichos compuestos; y uso en el tratamiento de enfermedades tal como cancer, fibrosis quistica, diabetes, enfermedad de alzheimer, entre otras. | |
| MY180626A (en) | Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof | |
| SI2176252T1 (sl) | 2,3-dihidrobenzo(1,4)dioksin-2-ilmetilni derivati kot alfa2C antagonisti za uporabo v zdravljenju bolezni perifernega in centralnega živčnega sistema | |
| CY1115725T1 (el) | Ενωσεις, συνθεσεις και μεθοδοι για την θεραπευτικη αγωγη των βητα-αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων | |
| EA200971107A1 (ru) | Катехоламиновые производные, полезные для лечения болезни паркинсона | |
| CL2009000727A1 (es) | Compuestos derivados de n-hidroxi-3-fenilprop-2-enemida y n-hidroxi-3-fenilpropanamida sustituidos; inhibidores de la enzima desacetilasa; su composicion farmaceutica; utiles en el tratamiento del cancer, tumores, psoriasis, alzheimer, entre otras. | |
| MY167575A (en) | Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases | |
| ATE489371T1 (de) | Benzamidglucokinaseaktivatoren |